SecBot SecBot
PRESS-RELEASE ·Filed Aug 10, 2026

SEPN

Septerna, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed3mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The EPS beat is entirely from non-dilutive collaboration revenue, not operational improvement, ignore for valuation. The key catalyst is SEP-479 SAD/MAD data in Q1 2027; binary event for hypoparathyroidism thesis. Monitor SEP-631 Phase 2 strategy update and TSHR candidate selection as next catalysts.

DirectionNeutral
Confidencemedium
Horizonmonths

Drugs in focus

SEPN drug pipeline →

SEP-479

● Neutral Named in this press release
Impact
Phase
Phase 1
Time to market
If Phase 1 data are positive, SEP-479 would still need to complete Phase 2 and Phase 3 trials before any potential FDA submission, placing a potential approval several years away (likely 2029-2031 at the earliest).
Next catalyst
None dated

What to watchThe next catalyst for SEP-479 is the Phase 1 topline safety, PK and PD data readout, guided for late 2026 or early 2027. Positive data would validate the oral small-molecule approach against an injectable standard of care (YORVIPATH) and could drive SEPN shares higher given the strong analyst consensus. Negative data (safety signals or poor PK/PD) would be a significant setback for Septerna's lead wholly-owned program.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$47.76
T+0 close · Aug 10, 2026 · via day close
Latest settled
+0.25%
T+60 · $47.88
Vs SPY
+0.74%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 11 $47.76entry
  2. T+1 · 3mo ago +0.90%α +0.65% · $48.19
  3. T+5 · 3mo ago −8.29%α −7.89% · $43.80
  4. T+20 · 2mo ago −20.50%α −19.44% · $37.97
  5. T+60 · 13d ago +0.25%α +0.74% · $47.88
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Septerna reported Q2 2026 financial results highlighting a net loss of $13.0M (EPS -$0.29) vs consensus of -$0.48, a 39.6% beat. Pipeline progress was steady: SEP-479 Phase 1 PK supports once-daily dosing with SAD/MAD data expected Q1 2027; SEP-631 Phase 1 data positive; TSHR NAM advancing toward candidate selection. Cash of $516.5M funds operations into 2029. Collaboration revenue of $26.7M from Novo Nordisk drove the beat, but as a clinical-stage biotech this is non-core milestone/amortization revenue, the EPS surprise is mechanical, not growth-driven.

Key Financial Metrics

EPS
−$0.29
est −$0.48 · +39.6%
Revenue
$26.7M
est $19.2M · +39.1% · +22438.7% YoY
Rating
beat

Key Facts

  • Net loss was $13.0M for Q2 2026 vs $24.8M in Q2 2025; EPS -$0.29 vs consensus -$0.48 (beat).
  • Revenue of $26.7M from Novo Nordisk collaboration (amortization of $14.6M upfront + $0.9M milestones + $11.2M research services).
  • SEP-479 Phase 1 ongoing; observed half-life ~3–4 days supports once-daily dosing; SAD/MAD data expected Q1 2027.
  • SEP-631 Phase 1 results reported March 2026: well-tolerated, once-daily PK, robust skin wheal suppression; evaluating Phase 2 strategies.
  • TSHR NAM program progressing toward development candidate selection for Graves' disease / thyroid eye disease.
  • Cash position $516.5M; expected runway into 2029.
  • R&D expenses $35.1M (up 58% YoY) and G&A $8.5M (up 23% YoY) reflecting clinical ramp.

Financial Impact

EPS beat of $0.19 vs $0.48 consensus (39.6%) driven by Novo Nordisk collaboration revenue, non-core to pipeline valuation. Cash burn rate ~$18M/quarter implies 7+ years runway.

epsnetLosscashPosition

Risk Factors

  • SEP-479 Phase 1 data delayed to Q1 2027; MAD cohort extension may increase development timeline risk.
  • SEP-631 Phase 2 strategy undefined, potential for pivot or failure in mast cell-driven diseases.
  • Pre-revenue clinical-stage biotech with no approved products; valuation tied entirely to pipeline milestones.
  • R&D spend increasing 58% YoY with no near-term revenue growth from non-collaboration sources.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3342181

US Market Status

Market Closed · Opens Wed (12h 46m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026